# Incyte Moat

Status: published. Policy: company-analysis-1.

Incyte has a narrow intangible-asset advantage supported by commercialized proprietary medicines, exclusive licensed rights and recurring royalties from monetized intellectual property. These demonstrate a current advantage, but the passages do not establish its remaining exclusivity runway or superiority against specific competing treatments. Pricing power is constrained by substantial rebates and government controls; sustained net price increases are not demonstrated. Pipeline forecasts do not establish future moat replacement.

## intangible_assets

Commercialized proprietary therapeutics and licensed intellectual property generate product sales, recurring royalties and realized milestone payments. Exclusive worldwide development and commercialization rights under the disclosed MacroGenics agreement provide a specific contractual barrier. Together these support a bounded current intangible-asset advantage.

Durability: Recurring royalty growth and multiyear product revenue growth support persistence, but product-specific patent expirations, exclusivity periods and license termination terms are absent. A narrow advantage is supported; exceptional or decade-long durability is not established.

Risks: Loss of exclusivity, patent circumvention, impaired in-licensed rights and collaborator dependence could erode economics. Government pricing restrictions and substantial rebates constrain monetization. Management's projected pipeline sales and growth beyond Jakafi remain potential rather than demonstrated replacement economics.

Invalidation: The assessment would fail if loss or circumvention of relevant rights allowed equivalent offerings to materially displace sales or royalties, if exclusive licenses ended without adequate replacement, or if reimbursement restrictions persistently impaired the portfolio's commercial economics. Subsequent disclosures showing that the monetized rights provide no meaningful exclusion would also invalidate the claimed barrier.

Competitors: Not established
- [https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm](https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm) · 2026-02-10
- [https://www.sec.gov/Archives/edgar/data/879169/000087916926000056/incy-20260630.htm](https://www.sec.gov/Archives/edgar/data/879169/000087916926000056/incy-20260630.htm) · 2026-07-28
- [https://www.sec.gov/Archives/edgar/data/879169/000087916926000031/incy-20260428.htm](https://www.sec.gov/Archives/edgar/data/879169/000087916926000031/incy-20260428.htm) · 2026-04-28

[JSON](https://beanvest.com/stock/incy/moat.json)